On Tuesday shares of ArQule Inc. (NASDAQ:ARQL) closed at $2.27. Company’s sales growth for last 5 years was -14.80% and EPS growth for next 5 years is recorded as 5.00%. Research analysts at Leerink Swann raised their price objective on shares of ArQule (NASDAQ:ARQL) from $4.00 to $5.00 in a report released on Thursday. The firm currently has an “outperform” rating on the stock. Leerink Swann’s target price would suggest a potential upside of 145.10% from the company’s current price.
Pfizer Inc. (NYSE:PFE) in last trading activity moved down -0.78% to close at $34.17. Company weekly performance is 1.15% while its quarterly performance stands at 11.38%. Pfizer Inc. (NYSE:PFE) is -2.29% away from its 52 week high. Pfizer Inc. (NYSE:PFE) CEO Ian Read got a nice pay bump for 2015, with a total package of $23.3 million–more than one-quarter bigger than the previous year’s total. But a big chunk of that increase came in the value of his pension. Back that out, and Read’s compensation only grew by $280,000.
On last trading day HSBC Holdings plc (ADR) (NYSE:HSBC) moved up 1.20% to close at $42.25. Its volatility for the week is 0.85% while volatility for the month is 0.84%. HSBC’s sales growth for past 5 years was -3.90% and its EPS growth for past 5 years was 15.30%. HSBC Holdings plc (ADR) (NYSE:HSBC) monthly performance is -6.32%. HSBC Holdings plc (ADR) (NYSE:HSBC)’s Floating Rate Non-Cumulative Preferred Stock, Series F (Symbol: HUSI.PRF) will trade ex-dividend, for its quarterly dividend of $0.2163, payable on 4/1/15.
Express Scripts Holding Company (NASDAQ:ESRX) has 0.20% insider ownership while its institutional ownership stands at 88.70%. In last trading activity company’s stock closed at $83.01. On March 11, it was reported that, Branded drugs are becoming increasingly expensive due to double-digit brand inflation along with continued rise in the price of specialty drugs. As per new data released from pharmacy benefit manager (PBM) Express Scripts Holding Company (NASDAQ:ESRX), new expensive HCV therapies coupled with the exploitation of loopholes for compounded medications, fueled a phenomenal 13.1% surge in drug spending in the U.S. in 2014. HCV and compounded medications accounted for more than half of the total increase in expenditure.
On last trading day Liquidity Services, Inc. (NASDAQ:LQDT) moved down -2.17% to close at $9.45. Its volatility for the week is 2.91% while volatility for the month is 3.37%. LQDT’s sales growth for past 5 years was 17.70% and its EPS growth for past 5 years was 26.50%. Liquidity Services, Inc. (NASDAQ:LQDT) monthly performance is -0.74%. On March 11, it was reported that, Liquidity Services, Inc. (NASDAQ:LQDT) has teamed up with Valtecsa, a subsidiary of Krata, SA, an appraisals firm specializing in real estate in accordance with the ECO normative in Spain and Portugal.